Abstract:
Background: - Multi Drug Resistance Tuberculosis is a growing public health problem in
all over the world. The treatment of Multi drug resistance tuberculosis is very important
because of the risk of transmitting virtually untreatable drug resistant disease. When
patients are not timely and appropriately assessed and managed for adverse effects of
second line drugs the consequence will be life treating.
Objective: - To determine Magnitude of adverse effect in Multi drug resistance
tuberculosis treatment and associated factors at St Peters TB specialized hospital and
Gondar university hospital, Ethiopia.
Method: - Institution based retrospective cross sectional study was conducted from April
1-20, 2014. A total of 540 patients were enrolled in this study and data was collected using
pre tested structured check list by trained health professional. The collected data was
reviewed and checked for completeness before data entry, coded and entered to Epi-info
version 3.5.1 and was exported to SPSS version 20 for descriptive. Bivariate and
multivariate logistic regression model were used to identify the associated factors of
adverse effects. The degree of association between independent and dependent variables
was assessed by using odds ratio with its 95% confidence interval.
Results: -. A total of 486 (90%) patients had at least one adverse effect while on treatment
of Multi drug resistance tuberculosis. The most common adverse effects are severe
gastritis (72.96%) followed by Arthralgia (limit mobility) (40.74%) and psychiatric disorder
(30.56%). Body mass index less than 16.5kg/m2 [AOR: 2.83, 95% CI: (1.57-5.08)] and
HIV positive patients [AOR: 2.34, 95% CI: (1.14-4.79)] are significantly associated with
Multi drug resistance tuberculosis treatment adverse effect.
Conclusion: - The prevalence of common adverse effect on Multi drug resistance
tuberculosis treatment was high. Nutritional and HIV status are the associated factors for
drug adverse effect. Therefore, especial emphasis for malnourished and HIV co infected
patients should be given while they are taking anti Multi drug resistance tuberculosis
treatment at treatment initiating centers.
